March 18, 2018 10:43 AM ET

Healthcare Equipment and Supplies

Company Overview of VENITI, Inc.

Company Overview

VENITI, Inc., a medical device company, engages in developing technologies and solutions for treatment across the venous disease continuum. Its VENITI VICI VENOUS STENT system comprises a stent implant that includes closed-cell segments, and bridges and braces to provide strength and flexibility in the venous anatomy; and a disposable delivery system, which includes an exterior shaft to protect and constrain the stent prior to deployment. The company offers its product for commercial use in the European Union. VENITI, Inc. was founded in 2010 and is based in St. Louis, Missouri with technical operations in Fremont, California.

1610 Des Peres Road

Suite 385

St. Louis, MO 63131

United States

Founded in 2010





Key Executives for VENITI, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer
Director of R&D Engineering and Operations
Chief Commercialization Officer
Vice President of Technology, Clinical Research, and Regulatory Affairs
Age: 58
Compensation as of Fiscal Year 2017.

VENITI, Inc. Key Developments

VENITI, Inc. Announces Boston Scientific Distribution Agreement for VICI VENOUS STENT

VENITI, Inc. announced that Boston Scientific will distribute the VICI VENOUS STENT under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed. Launched in 2014, the VICI VENOUS STENT has gained wide market acceptance for the unique balance of end-to-end strength, flexibility and lumen quality for addressing the challenging requirements of venous disorders. It is available in a conventional delivery system, as well as the novel VICI VERTO VENOUS STENT System, providing more control in the landing of stents in areas of critical blood flow. The VICI VENOUS STENT is widely recognized as technology for venous stents and physicians routinely praise the product for its performance qualities. Venous obstructive disease affects more than 1.1 million people in the United States and Western Europe annually. Deep venous thrombosis is one of the most common and serious conditions associated with chronic venous disease and the financial impact is well established. Physicians treat the obstructive component of chronic venous disease through minimally-invasive endovascular stenting procedures. VENITI is currently conducting the VIRTUS Trial to evaluate the safety and efficacy of the VICI VENOUS STENT for the treatment of chronic iliofemoral venous outflow obstruction under a U.S. Food and Drug Administration Investigational Device Exemption.


VENITI, Inc. announced the successful treatment of the first patient suffering from Post Thrombotic Syndrome associated with venous outflow obstruction with the VICI VERTO VENOUS STENT System. This innovative stent delivery system allows the physician to deploy a venous stent beginning at the peripheral end of the common femoral vein. The stent system received CE Marking on April 1, 2016. The announcement comes ahead of next week's Charing Cross Symposium in London UK, where the company will preview the product, along with the already-released VICI VENOUS STENT®. Post Thrombotic Syndrome is a complication of deep vein thrombosis, which affects more than 1.4 MM people across the United States and Western Europe each year. It is estimated that 20-50% of the people who have had a deep vein thrombosis will develop Post Thrombotic Syndrome. Post Thrombotic Syndrome can have devastating, long-term consequences affecting the quality of life for the thousands of people who suffer from the condition. Symptoms include progressive leg pain and swelling, leg heaviness and skin changes. Physicians treat the obstructive component of Post Thrombotic Syndrome through minimally-invasive endovascular stenting procedures. The VIRTUS Trial is being performed under a U.S. Food and Drug Administration Investigational Device Exemption to evaluate the safety and efficacy of the VICI VENOUS STENT for the treatment of chronic iliofemoral venous outflow obstruction.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VENITI, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at